These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34260914)

  • 1. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
    Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
    Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS
    Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells.
    Höpner SS; Raykova A; Radpour R; Amrein MA; Koller D; Baerlocher GM; Riether C; Ochsenbein AF
    Nat Commun; 2021 Feb; 12(1):1065. PubMed ID: 33594067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.
    Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P
    Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
    Shah M; Bhatia R
    Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
    Lefort S; Maguer-Satta V
    Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Agarwal P; Zhang B; Ho Y; Cook A; Li L; Mikhail FM; Wang Y; McLaughlin ME; Bhatia R
    Blood; 2017 Feb; 129(8):1008-1020. PubMed ID: 28011678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
    Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson AS; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
    Blood; 2023 Jul; 142(1):73-89. PubMed ID: 37018663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.
    Zhang B; Chu S; Agarwal P; Campbell VL; Hopcroft L; Jørgensen HG; Lin A; Gaal K; Holyoake TL; Bhatia R
    Blood; 2016 Dec; 128(23):2671-2682. PubMed ID: 27621307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
    Baquero P; Dawson A; Mukhopadhyay A; Kuntz EM; Mitchell R; Olivares O; Ianniciello A; Scott MT; Dunn K; Nicastri MC; Winkler JD; Michie AM; Ryan KM; Halsey C; Gottlieb E; Keaney EP; Murphy LO; Amaravadi RK; Holyoake TL; Helgason GV
    Leukemia; 2019 Apr; 33(4):981-994. PubMed ID: 30185934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.